Unleashing the Power of Tregs

Multiple Treg therapeutic modalities addressing neurodegenerative, autoimmune, and metabolic diseases

We are a clinical-stage company focused on developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Strong proof of concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s

Treg Enhancing Biologics:

Treg Enhancing
Biologics:

Allogeneic Treg
Derived Exosomes:

Autologous Treg
Cell Therapy:

Video

News

Keep up-to-date with the latest news about Coya Therapeutics.

Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases

Sept. 07, 2023

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies

Aug 31, 2023

The publication reports the analyses of blood biomarker data from a cross sectional cohort of sporadic ALS patients (n = 30) and healthy controls (n=10)...

Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023

Aug 25, 2023

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages...

Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors

Aug 21, 2023

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function...

Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results

Aug 8, 2023

Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

Aug 3, 2023

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced that...